Imidacloprid and Moxidectin Spot-on Solutions (for Dogs)

Ingredients: Imidacloprid, Moxidectin.

Appearance: Yellow to brownish-yellow liquid.

Pharmacological Effects:Antiparasitic drug.

Pharmacodynamics: Imidacloprid is a new-generation chloronicotinyl insecticide with high affinity for postsynaptic nicotinic acetylcholine receptors in the insect central nervous system. It inhibits acetylcholine transmission, leading to paralysis and death of parasites. It is effective against adult fleas and all immature flea stages, and also has activity against flea larvae in the environment.
Moxidectin has a mechanism of action similar to avermectins and ivermectin and exhibits strong activity against internal and external parasites, especially nematodes and arthropods. Its antiparasitic effect is achieved by promoting the release of the neurotransmitter γ-aminobutyric acid (GABA), enhancing its binding to postsynaptic receptors and opening chloride ion channels. Moxidectin also shows selective and high affinity for glutamate-gated chloride channels, disrupting neuromuscular signal transmission, causing flaccid paralysis and death of parasites. The target sites are inhibitory interneurons and excitatory motor neurons in nematodes, and neuromuscular junctions in arthropods. The combination of imidacloprid and moxidectin provides a synergistic effect.
Pharmacokinetics: After the first administration, imidacloprid rapidly distributes over the dog’s body surface on the same day and remains present on the skin throughout the dosing interval. Plasma concentrations of moxidectin reach peak levels within 4–9 days after administration and are distributed systemically, followed by slow metabolism and elimination over approximately one month.

Indications:

For the prevention and treatment of internal and external parasitic infections in dogs, including prevention and treatment of flea infestations (Ctenocephalides felis); treatment of lice infestations (Trichodectes canis); treatment of ear mite infestations (Otodectes cynotis), sarcoptic mange (Sarcoptes scabiei var. canis), and demodicosis (Demodex canis); treatment of angiostrongylosis and gastrointestinal nematode infections (adult, immature adult, and L4 larvae of Toxocara canis, Ancylostoma caninum, and Uncinaria stenocephala; adult Toxascaris leonina and Trichuris vulpis); prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis); and treatment of circulating microfilariae (Dirofilaria immitis). This product may also be used as part of a treatment program for flea allergy dermatitis (FAD).

Dosage and Administration:

Calculated based on this product. For external use only. A single dose of 0.1 ml per kg body weight in dogs. Administer once monthly during prevention or treatment periods. To prevent licking, apply the product to the skin on the back of the dog between the shoulder blades and hips, dividing the dose into 3–4 application sites if necessary.

Recommended Dosage Table for Dogs

Flea prevention and treatment: A single administration prevents reinfestation for up to 4 weeks. Existing flea pupae in the environment may hatch for 6 weeks or longer depending on climate. To interrupt the flea life cycle, environmental control measures should be used concurrently.
Lice infestations: Single administration; reassess after 30 days to determine the need for a second treatment.
Ear mite infestations: Single administration; remove loose debris from the external ear canal prior to treatment. Reassess after 30 days to determine the need for a second treatment.
Sarcoptic mange: Administer once every 4 weeks for two consecutive treatments.
Demodicosis: Administer once every 4 weeks for 2–4 months. In severe cases, longer and more frequent treatment may be required, including weekly administration under veterinary supervision. Treatment should continue until skin scrapings are normal for at least two consecutive months. Dogs showing no improvement after two months should discontinue use and receive alternative therapy as directed by a veterinarian.
Angiostrongylosis: Single administration; reassess after 30 days to determine the need for a second treatment. Monthly administration in endemic areas can prevent larval migration and significant infection.
Heartworm prevention: Dogs living in or traveling to heartworm-endemic areas may be treated year-round or starting one month before mosquito season, administered once monthly until one month after the end of mosquito activity. When switching from another heartworm preventive, the first dose should be administered within one month of the last dose of the previous product.
Treatment of circulating microfilariae: Administer once monthly for two consecutive doses.

Adverse Reactions:

1. Transient pruritus may occur. Rarely (>1/10,000 to <1/1,000), hair clumping, erythema, or vomiting may be observed; these reactions usually resolve without treatment. Local allergic reactions may occasionally occur.

2. If the animal licks the application site, very rare cases (<1/10,000) may show transient neurological signs such as excitation, tremors, ocular signs (mydriasis, reduced pupillary reflex, nystagmus), abnormal respiration, salivation, or vomiting. Transient behavioral changes such as reluctance to move, excitation, or reduced appetite may also occur.

3. Field studies indicate that heartworm-positive dogs with microfilaremia may be at risk of severe respiratory signs (coughing, tachypnea, dyspnea) and may require immediate veterinary treatment. Gastrointestinal signs (vomiting, diarrhea, decreased appetite) and lethargy are also commonly observed after administration.

Precautions:

1. Contraindicated in dogs younger than 7 weeks of age and in dogs hypersensitive to this product or its excipients. Safety has not been evaluated in pregnant or lactating dogs; use only under veterinary advice.

2. Dogs weighing less than 1 kg should be treated only under veterinary guidance.

3. Do not use in dogs with Class IV heartworm disease, as safety has not been evaluated in this population. Safety has only been assessed in dogs with Class I or II heartworm disease in laboratory studies and limited Class III cases in field studies. Risk assessment is required for dogs with obvious or severe heartworm disease.

4. Although overdose studies suggest safety in dogs infected with adult heartworms, this product does not treat adult Dirofilaria immitis. Dogs aged 6 months or older in endemic areas should be tested for adult heartworm infection prior to use. The safety of concurrent administration with adulticidal therapy on the same day has not been evaluated.

5. This product contains moxidectin (a macrocyclic lactone); special care should be taken to prevent oral ingestion in Collies, Old English Sheepdogs, and related breeds.

6. Use with caution in sick or debilitated dogs under veterinary supervision.

7. Do not use in cats.

8. Avoid contact of the product with the eyes or mouth of treated animals or other animals. Prevent animals from licking each other until the application site is dry. Do not touch or groom the hair before drying.

9. Occasional exposure to water (once or twice) during the treatment period does not significantly affect efficacy; frequent bathing or immersion may reduce effectiveness.

10. Keep out of reach of children.

11. Do not store above 30°C. Do not use beyond the expiration date.

12. Persons hypersensitive to this product should avoid handling it.

13. When administering, avoid contact with skin, eyes, and mouth. Do not eat, drink, or smoke during use. Wash hands thoroughly after application. If contact with skin or eyes occurs, rinse immediately with soap and water or clean water. Seek medical attention if symptoms persist.

14. There is no specific antidote. In case of accidental ingestion, oral administration of activated charcoal may aid detoxification.

15. The solvent in this product may stain or damage leather, fabrics, plastics, and painted surfaces; avoid contact until the application site is dry.

16. Do not allow this product to enter surface waters.

17. Dispose of unused product and packaging in accordance with local regulations.

Withdrawal Period: Not required.

Specifications:
(1) 0.4 ml: Imidacloprid 40 mg + Moxidectin 10 mg
(2) 1.0 ml: Imidacloprid 100 mg + Moxidectin 25 mg
(3) 2.5 ml: Imidacloprid 250 mg + Moxidectin 62.5 mg
(4) 4.0 ml: Imidacloprid 400 mg + Moxidectin 100 mg

Package: 3tubes/box

Storage: Store in a tightly sealed container.
Shelf Life: 36 months